MDXH:NASDAQMDxHealth SA Analysis

MDxHealth SA (MDXH) trades at $2.20, well below its 20‑day SMA of $2.43 and the analyst median target of $7.0, indicating a sizable valuation gap. The stock’s RSI of 33 points to near‑oversold conditions, while the MACD line has just crossed above its signal line, generating a bullish signal. Support sits at $1.96 and resistance at $3.29, giving the price a modest cushion above the nearest floor. Revenue grew 19% YoY to $108 M with a strong 64.5% gross margin, but operating margins remain deeply negative (‑18%) and cash conversion is negative. The balance sheet shows $86.6 M of debt against $29.1 M of cash, resulting in a high leverage profile and a negative book value per share. Volatility is elevated at 60% over the past 30 days and beta of ~1.8 signals heightened sensitivity to market swings. The recent Oxford ProMPT study presented at EAU 2026 validated the Genomic Prostate Score, a key product that could accelerate adoption across Europe and the U.S.
Analysts (5) have issued a “strong buy” consensus with a mean price target of $7.4, implying a potential upside of over 200%. The company’s price‑to‑sales multiple of ~1.0 is modest relative to the industry average, yet the negative earnings and free‑cash‑flow deficits underscore execution risk. No dividend is paid, so income‑focused investors have no yield cushion. Regulatory approval pathways for diagnostic assays remain a key hurdle, but the partnership with the University of Oxford adds credibility. Geographic exposure spans the U.S. and Europe, diversifying revenue sources but introducing currency considerations. Given the blend of near‑term technical support and long‑term growth catalysts, the stock presents a high‑risk, high‑reward profile. Investors should weigh the upside potential against the substantial earnings and liquidity challenges before committing capital.